1Y Target$28.00Near-term target
5Y Target$31.22Compound horizon
10Y Target$81.23Long-dated conviction
FCF$123mTTM · 03/26CFCF $123m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+78.8%TTM YoYARevenue +78.8% — hypergrowth, top decile
D/E0.73BD/E 0.73 — at market average, manageable
P/S4.8xBP/S 4.8x — in line with software/tech peers
PEG——PEG not meaningful — earnings growth negative or data unavailable
Why now
Biotechnology · market cap $4.4b. Down 63% from 52-week high of $42.50 — deep drawdown territory. Revenue growing +79% — in hypergrowth territory. 13 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $28.00 (implying +80% upside).
Moat
ROE 28% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Down 63% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Net margin 3.7% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $28.00 (13-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $31.22 — requires the platform / technology to reach commercial scale. 10 yr $81.23 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.